These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 9568689)

  • 1. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice.
    Liang L; Beshay E; Prud'homme GJ
    Diabetes; 1998 Apr; 47(4):570-5. PubMed ID: 9568689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of phosphodiesterase isoforms III or IV suppress islet-cell nitric oxide production.
    Beshay E; Prud'homme GJ
    Lab Invest; 2001 Aug; 81(8):1109-17. PubMed ID: 11502862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo.
    Beshay E; Croze F; Prud'homme GJ
    Clin Immunol; 2001 Feb; 98(2):272-9. PubMed ID: 11161985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of anti-CD3-induced interleukin-4 and interleukin-5 release from splenocytes of Mesocestoides corti-infected BALB/c mice by phosphodiesterase 4 inhibitors.
    Souness JE; Houghton C; Sardar N; Withnall MT
    Biochem Pharmacol; 1999 Sep; 58(6):991-9. PubMed ID: 10509751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
    Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
    Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 independent.
    Haskó G; Szabó C; Németh ZH; Salzman AL; Vizi ES
    Eur J Immunol; 1998 Feb; 28(2):468-72. PubMed ID: 9521054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
    Griswold DE; Webb EF; Badger AM; Gorycki PD; Levandoski PA; Barnette MA; Grous M; Christensen S; Torphy TJ
    J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
    Badger AM; Olivera DL; Esser KM
    Circ Shock; 1994 Dec; 44(4):188-95. PubMed ID: 7628060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells.
    Yoshimura T; Kurita C; Nagao T; Usami E; Nakao T; Watanabe S; Kobayashi J; Yamazaki F; Tanaka H; Nagai H
    Gen Pharmacol; 1997 Oct; 29(4):633-8. PubMed ID: 9352314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation.
    Jimenez JL; Punzón C; Navarro J; Muñoz-Fernández MA; Fresno M
    J Pharmacol Exp Ther; 2001 Nov; 299(2):753-9. PubMed ID: 11602691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
    Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
    J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
    Sinha B; Semmler J; Eisenhut T; Eigler A; Endres S
    Eur J Immunol; 1995 Jan; 25(1):147-53. PubMed ID: 7843225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphocyte suppression by rolipram with other immunosuppressive drugs.
    Briggs WA; Wu Q; Orgul O; Choi M; Scheel PJ; Burdick J
    J Clin Pharmacol; 1999 Aug; 39(8):794-9. PubMed ID: 10434230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the phosphodiesterase IV inhibitor rolipram on Th1 and Th2 immune responses in mice.
    Yamaki K; Li X; Uchida H; Alam AH; Hossain MA; Yanagisawa R; Takano H; Taneda S; Hayashi H; Mori Y; Yoshino S
    J Pharm Pharmacol; 2004 Jul; 56(7):877-82. PubMed ID: 15233866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
    Blease K; Burke-Gaffney A; Hellewell PG
    Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.
    Angel JB; Saget BM; Walsh SP; Greten TF; Dinarello CA; Skolnik PR; Endres S
    AIDS; 1995 Oct; 9(10):1137-44. PubMed ID: 8519449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difference in preventive effects between the phosphodiesterase iv inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice.
    Yamaki K; Li X; Hossain MA; Alam AH; Taneda S; Yanagisawa R; Takano H; Yoshino S
    Immunol Invest; 2007; 36(2):131-45. PubMed ID: 17365015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.